

Gareth J Veal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3304358/publications.pdf>

Version: 2024-02-01

115
papers

4,156
citations

136950
32
h-index

128289
60
g-index

118
all docs

118
docs citations

118
times ranked

6130
citing authors

#	ARTICLE	IF	CITATIONS
1	Human renal function maturation: a quantitative description using weight and postmenstrual age. <i>Pediatric Nephrology</i> , 2009, 24, 67-76.	1.7	406
2	Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1397-1410.	10.7	352
3	Review of therapeutic drug monitoring of anticancer drugs part two “ Targeted therapies. <i>European Journal of Cancer</i> , 2014, 50, 2020-2036.	2.8	248
4	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. <i>New England Journal of Medicine</i> , 2018, 378, 2376-2385.	27.0	217
5	Review of therapeutic drug monitoring of anticancer drugs part 1 “ Cytotoxics. <i>European Journal of Cancer</i> , 2014, 50, 2010-2019.	2.8	205
6	Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 6091-6100.	3.4	137
7	Metabolism of zidovudine. <i>General Pharmacology</i> , 1995, 26, 1469-1475.	0.7	103
8	Clinical Pharmacology in the Adolescent Oncology Patient. <i>Journal of Clinical Oncology</i> , 2010, 28, 4790-4799.	1.6	93
9	The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. <i>Aids</i> , 1996, 10, 1361-1367.	2.2	86
10	The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. <i>Cancer Cell</i> , 2018, 34, 626-642.e8.	16.8	81
11	Therapeutic drug monitoring in cancer “ Are we missing a trick?. <i>European Journal of Cancer</i> , 2014, 50, 2005-2009.	2.8	79
12	Lamivudine (3TC) phosphorylation and drug interactions in vitro. <i>Biochemical Pharmacology</i> , 1997, 54, 589-595.	4.4	68
13	Oxazaphosphorines: new therapeutic strategies for an old class of drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 919-938.	3.3	65
14	Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. <i>Aids</i> , 1994, 8, F1-1024.	2.2	59
15	A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. <i>British Journal of Cancer</i> , 2001, 84, 1029-1035.	6.4	55
16	Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. <i>European Journal of Cancer</i> , 2012, 48, 3063-3072.	2.8	54
17	Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study. <i>Clinical Cancer Research</i> , 2005, 11, 5893-5899.	7.0	53
18	Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma “ a study of the United Kingdom Children's Cancer Study Group. <i>British Journal of Cancer</i> , 2007, 96, 424-431.	6.4	52

#	ARTICLE	IF	CITATIONS
19	Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 613-622.	4.9	48
20	Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treatment Reviews, 2003, 29, 253-273.	7.7	46
21	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. European Journal of Cancer, 2016, 55, 56-64.	2.8	46
22	Adaptive Dosing Approaches to the Individualization of 13- <i>cis</i> -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. Clinical Cancer Research, 2013, 19, 469-479.	7.0	45
23	Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research, 2001, 7, 2205-12.	7.0	45
24	13- <i>cis</i> Retinoic acid and isomerisation in paediatric oncology—“is changing shape the key to success?”. Biochemical Pharmacology, 2005, 69, 1299-1306.	4.4	44
25	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. British Journal of Cancer, 2005, 92, 696-704.	6.4	44
26	Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MABs, 2016, 8, 604-616.	5.2	43
27	<i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. Cancer Research, 2019, 79, 5382-5393.	0.9	42
28	Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorganic and Medicinal Chemistry, 2008, 16, 8301-8313.	3.0	41
29	Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Molecular Cancer Therapeutics, 2006, 5, 541-555.	4.1	39
30	Drug interactions with zidovudine phosphorylation in vitro. Antimicrobial Agents and Chemotherapy, 1995, 39, 1376-1378.	3.2	37
31	Adaptive dosing and platinum—DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer, 2007, 96, 725-731.	6.4	35
32	Carboplatin therapeutic monitoring in preterm and full-term neonates. European Journal of Cancer, 2015, 51, 2022-2030.	2.8	34
33	Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European Journal of Cancer, 2010, 46, 1841-1847.	2.8	33
34	Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer. Clinical Pharmacokinetics, 2014, 53, 741-751.	3.5	33
35	Influence of isomerisation on the growth inhibitory effects and cellular activity of 13- <i>cis</i> and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology, 2002, 63, 207-215.	4.4	32
36	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology, 2013, 85, 29-37.	4.4	32

#	ARTICLE	IF	CITATIONS
37	Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. <i>Clinical Cancer Research</i> , 2019, 25, 5094-5106.	7.0	32
38	Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. <i>British Journal of Cancer</i> , 2007, 96, 1675-1683.	6.4	30
39	Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. <i>Aids</i> , 1996, 10, 546-548.	2.2	29
40	Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics. <i>British Journal of Cancer</i> , 2004, 90, 60-64.	6.4	29
41	Intracellular Activation of 2',3'-Dideoxyinosine and Drug Interactions in Vitro. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 793-802.	1.1	28
42	Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2778-2791.	6.4	27
43	Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. <i>Haematologica</i> , 2019, 104, 1804-1811.	3.5	27
44	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 989-998.	2.4	26
45	Chemotherapy in newborns and preterm babies. <i>Seminars in Fetal and Neonatal Medicine</i> , 2012, 17, 243-248.	2.3	25
46	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. <i>Leukemia</i> , 2021, 35, 2552-2562.	7.2	25
47	A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 6830-6839.	7.0	24
48	Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 323-328.	2.4	23
49	Population Pharmacokinetic Investigation of Actinomycin in Children and Young Adults. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 35-42.	2.0	23
50	Synthesis and Biological Evaluation of 3-(1 <i>H</i> -imidazol- and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td (Triazol-1-yl)-2,2-dimethyl Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6803-6811.	6.4	23
51	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. <i>International Journal of Cancer</i> , 2019, 144, 3146-3159.	5.1	23
52	Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 685-692.	2.3	22
53	A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. <i>Pediatric Blood and Cancer</i> , 2007, 48, 687-695.	1.5	21
54	Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1261-1266.	3.3	21

#	ARTICLE	IF	CITATIONS
55	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography–mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 795, 237-243.	2.3	20
56	Novel micelles based on amphiphilic branched PEG as carriers for fenretinide. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 880-890.	3.3	20
57	Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 13-24.	2.5	20
58	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26351.	1.5	20
59	Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. <i>European Journal of Cancer</i> , 2011, 47, 1556-1563.	2.8	19
60	Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. <i>European Journal of Cancer</i> , 2022, 164, 127-136.	2.8	19
61	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 547-558.	2.3	18
62	Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial. <i>European Journal of Cancer</i> , 2019, 120, 75-85.	2.8	18
63	Chemotherapy individualization. <i>Investigational New Drugs</i> , 2003, 21, 149-156.	2.6	17
64	Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 749-752.	2.3	17
65	Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1057-1066.	2.3	17
66	Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?. <i>Pediatric Blood and Cancer</i> , 2006, 46, 723-727.	1.5	16
67	Retinoid X receptors and retinoid response in neuroblastoma cells. <i>Journal of Cellular Biochemistry</i> , 2002, 86, 67-78.	2.6	15
68	Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1211-1217.	3.3	15
69	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. <i>British Journal of Pharmacology</i> , 2011, 162, 989-999.	5.4	14
70	Therapy-induced carboplatin–DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. <i>Biochemical Pharmacology</i> , 2012, 83, 69-77.	4.4	14
71	Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib. <i>JAMA Dermatology</i> , 2018, 154, 913.	4.1	14
72	In Vitro Screening of Nucleoside Analog Combinations for Potential Use in Anti-HIV Therapy. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 481-484.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 295-300.	2.3	13
74	Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td (triazol-5-yl)propanoates. <i>Journal of Medicinal Chemistry</i> , 2012, 20, 4201-4207.	3.0	13
75	Zalcitabine (ddC) Phosphorylation and Drug Interactions. <i>Antiviral Chemistry and Chemotherapy</i> , 1995, 6, 379-384.	0.6	12
76	Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6080-6088.	3.0	12
77	Physiologically-Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 759-768.	2.5	12
78	Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. <i>Bioanalysis</i> , 2021, 13, 101-113.	1.5	12
79	Pharmacokinetics and Pharmacogenetics of 13-cis-Retinoic Acid in the Treatment of Neuroblastoma. <i>Therapie</i> , 2007, 62, 91-93.	1.0	11
80	Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. <i>European Journal of Cancer</i> , 2022, 164, 137-154.	2.8	11
81	Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. <i>British Journal of Cancer</i> , 2008, 99, 894-899.	6.4	10
82	Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 136-146.	2.4	10
83	Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. <i>Antiviral Research</i> , 1998, 38, 63-73.	4.1	9
84	Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 361-365.	2.3	9
85	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 142-159.	2.0	9
86	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. <i>European Journal of Cancer</i> , 2018, 91, 56-67.	2.8	8
87	Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. <i>Bioanalysis</i> , 2017, 9, 1001-1010.	1.5	7
88	Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. <i>Pharmaceutics</i> , 2021, 14, 272.	3.8	7
89	Final report of a phase I study of 2-hydroxyoleic acid (2OHOA) a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including recurrent high grade gliomas (rHGG).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2554-2554.	1.6	7
90	Biliary excretion of etoposide in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 415-417.	2.3	6

#	ARTICLE	IF	CITATIONS
91	Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 256-262.	2.4	6
92	Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib. <i>Current Drug Targets</i> , 2014, 15, 1312-1321.	2.1	6
93	Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. <i>BMJ Open</i> , 2022, 12, e059872.	1.9	6
94	The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. <i>Oncology Reports</i> , 2011, 27, 293-8.	2.6	5
95	Carboplatin Dosing in Infants With Retinoblastoma: A Case for Therapeutic Drug Monitoring. <i>Journal of Clinical Oncology</i> , 2012, 30, 3424-3424.	1.6	5
96	Blood volumes in pediatric clinical trials: a review of current regulations and guidance for research studies. <i>Clinical Investigation</i> , 2014, 4, 1005-1011.	0.0	5
97	Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial. <i>Cancers</i> , 2021, 13, 1868.	3.7	5
98	Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1193-1197.	1.5	4
99	Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. <i>BMC Research Notes</i> , 2018, 11, 520.	1.4	4
100	Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine-based estimates of renal function. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27672.	1.5	4
101	Development and validation of LC-MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors. <i>Bioanalysis</i> , 2017, 9, 279-288.	1.5	3
102	The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1575-1584.	1.9	3
103	Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations. <i>Frontiers in Oncology</i> , 2021, 11, 815040.	2.8	3
104	Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29722.	1.5	3
105	Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 763-768.	2.3	2
106	A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13115.	3.4	2
107	Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey. <i>BMJ Paediatrics Open</i> , 2017, 1, e000170.	1.4	1
108	The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27825.	1.5	1

#	ARTICLE	IF	CITATIONS
109	Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 235-244.	0.8	1
110	Dexamethasone Accumulation in Dexamethasone Sensitive and Resistant Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 5140-5140.	1.4	1
111	Dosing of Cancer Patients with Low or Absent Renal Function. <i>Therapie</i> , 2007, 62, 117-120.	1.0	0
112	20 Estimating glomerular filtration rate (GFR) in children with cancer - impact of methodology on carboplatin dosing. <i>Nuclear Medicine Communications</i> , 2007, 28, A7.	1.1	0
113	Institutional Profile: Pharmacogenomics research at Newcastle University. <i>Pharmacogenomics</i> , 2012, 13, 1333-1338.	1.3	0
114	Pharmacogenetics and Cancer Treatment in Children. , 2010, , 101-113.		0
115	Phase II Study of Intravenous Etoposide in Patients with Relapsed Ependymoma (CNS 2001 04). <i>Neuro-Oncology Advances</i> , 2022, 4, vda053.	0.7	0